Ptc Therapeutics (PTCT) Cash from Financing Activities (2012 - 2026)

Ptc Therapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 31.96% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $328.1 million, a 23.93% increase from a year earlier, with the FY2025 full-year figure at $331.1 million, up 29.4% from the prior year.
• Cash from Financing Activities retreated to $6.4 million in Q1 2026 per PTCT's latest filing, from $302.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $620.5 million in Q4 2023 and bottomed at -$140.0 million in Q3 2022.
• The 5-year median for Cash from Financing Activities is $6.4 million (2026), against an average of $82.8 million.
• Biggest YoY gain for Cash from Financing Activities was 6857.23% in 2022; the steepest drop was 4804.13% in 2022.
• Year by year, Cash from Financing Activities stood at $302.9 million in 2022, then soared by 104.84% to $620.5 million in 2023, then plunged by 95.73% to $26.5 million in 2024, then jumped by 1042.78% to $302.5 million in 2025, then slumped by 97.88% to $6.4 million in 2026.
• Per Business Quant, the three latest PTCT Cash from Financing Activities figures stand at $6.4 million (Q1 2026), $302.5 million (Q4 2025), and $15.2 million (Q3 2025).